News

Lithea announces that its Chief Medical Officer Dr. Mathias Lidgren and Chief Technology Officer Dr. Deepak Raina participated in the Lund University Cancer Centre World Cancer Day event, where they presented new preclinical data supporting the potential of LIT1001 as an add‑on to the current MAP regimen for osteosarcoma.

During the session, Dr Lidgren and Dr Raina shared results from a recent mice study demonstrating that LIT1001 combined with MAP achieved superior tumour control compared to MAP alone, with stronger tumour‑growth inhibition and sustained local efficacy. The combination also maintained a favourable tolerability profile, reflecting the targeted intratumoral release mechanism of LIT1001.

“These findings strengthen the case for LIT1001 as a meaningful enhancement to standard osteosarcoma therapy,” said Lithea’s CMO. “Our goal is to bring a new level of precision to chemotherapeutic delivery while supporting better outcomes for patients who urgently need new options.”

The data presented aligns with Lithea’s development strategy for a planned first‑in‑human program and highlights the company’s growing traction within the oncology innovation ecosystem.

Download the poster as pdf: LIT1001 as an add-on local therapy to standard MAP treatment in osteosarcoma LUCC World Cancer Day 2026-02-05

Download this news as pdf: News Lithea AB – LUCC World Cancer Day

For more information about Lithea, please contact:

Ludvig Sjöberg, CEO
ludvig.sjoberg@lithea-pharma.com

February 6, 2026

Lund, Sweden

News

Contact

Lithea presents promising preclinical data at Lund University Cancer Centre’s World Cancer Day event

Patent granted in Japan

News

FEB 06, 2026Lithea presents promising preclinical data at Lund University Cancer Centre’s World Cancer Day eventLithea announces that its Chief Medical Officer Dr. Mathias Lidgren and Chief Technology Officer Dr. Deepak Raina participated in the Lund University …

JAN 27, 2026Patent granted in JapanCancer treatment company Lithea AB (“Lithea” or the “Company”), developer of the LIT-platform – a technology enabling local treatment of solid tumours…

OCT 24, 2025Lithea AB completes SEK 9.3 million directed share issue to advance preclinical development of LIT1001Lund, Sweden – October 24, 2025 – Lithea AB, a Swedish company working on new ways to treat cancer by delivering medicine directly into tumors, has su…

OCT 13, 2025Lithea secures Vinnova grant to advance international funding applicationLithea has been awarded a SEK 300,000 planning grant from Vinnova under the call Planning Grant for International Proposal 2025, part of the Global Co…

AUG 25, 2025Lithea announces appointment of Jostein Davidsen to Board of Directors Lithea is pleased to announce that Jostein Davidsen has been elected as a member of the Board of Directors. Jostein brings more than 35 years of inte…

JUL 23, 2025Lithea Receives U.S. FDA Orphan Drug Designation for Lead Osteosarcoma Therapy, LIT1001Lithea today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its lead investigational therapy…

JUN 23, 2025Lithea presents at Østdansk Sarkomgruppe meeting 2025On Monday, June 16th, 2025, Lithea’s Chief Medical Officer Mathias Lidgren, MD, PhD, and Chief Technical Officer Deepak Raina, PhD, presented Lithea’s…

MAY 22, 2025Lithea granted SME status by European Medicines Agency (EMA)We are pleased to announce that Lithea has been officially granted Small and Medium-sized Enterprise (SME) status by the European Medicines Agency (EM…

MAR 05, 2025Lithea’s technology showcased at ORS 2025 Annual meeting in Phoenix, Arizona, USWe are excited to share that our research team at Lund University recently attended the Orthopaedic Research Society’s (ORS) Annual Meeting in Phoenix…

MAR 03, 2025Exciting News: Moroxite T is Now Lithea!We’re thrilled to announce that Moroxite T is now Lithea! This change marks a new chapter in our journey as we continue to push the boundaries of phar…

Contact